Last reviewed · How we verify
NCT05073965
Vitamin D Supplementation Effect In Children With Pulmonary Tuberculosis Treatment
NA trial testing Vitamin D in Tuberculosis, Pulmonary in 84 participants. Completed in 30 July 2021.
30 July 2021
Quick facts
| Lead sponsor | Universitas Padjadjaran |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 84 |
| Start date | 1 December 2020 |
| Primary completion | 30 July 2021 |
| Estimated completion | 30 July 2021 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- Vitamin D
- Placebo
Conditions studied
- Tuberculosis, Pulmonary — all drugs for Tuberculosis, Pulmonary →
Sponsor
Universitas Padjadjaran — full company profile →
Who can join
Adults 6 to 18, any sex, with Tuberculosis, Pulmonary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the vitamin D supplementation effect to improve clinical outcomes in children with pulmonary tuberculosis treatment. This randomized, double-blind control trial with a cohort design was conducted in West Borneo from December 2020 - July 2021. A Total 84 patients met the inclusion criteria; aged 6 to 18 years old, newly diagnosed with pulmonary tuberculosis with vitamin D insufficiency. Only 80 patients completed the six months follow-up. The intervention was 1,000 IU vitamin D or placebo for six months treatment. Comparison of clinical conditions and nutritional status are analyzed statistically.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Host-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs.
Cubillos-Angulo JM, Nogueira BMF, Arriaga MB, Barreto-Duarte B, et al · · 2022 · cited 23× · PMID 36213651 · DOI 10.3389/fmed.2022.970408 -
Effects of Vitamin D supplementation on resolution of fever and cough in children with pulmonary tuberculosis: A randomized double-blind controlled trial in Indonesia.
Tamara L, Kartasasmita CB, Alam A, Gurnida DA. · · 2022 · cited 19× · PMID 35198149 · DOI 10.7189/jogh.12.04015 -
Host-directed therapy for tuberculosis.
Tian N, Chu H, Li Q, Sun H, et al · · 2025 · cited 14× · PMID 40211397 · DOI 10.1186/s40001-025-02443-4 -
Potential of Neuroinflammation-Modulating Strategies in Tuberculous Meningitis: Targeting Microglia.
Lu HJ, Guo D, Wei QQ. · · 2024 · cited 8× · PMID 37196131 · DOI 10.14336/ad.2023.0311 -
The advances in adjuvant therapy for tuberculosis with immunoregulatory compounds.
Mi J, Wu X, Liang J. · · 2024 · cited 5× · PMID 38966394 · DOI 10.3389/fmicb.2024.1380848 -
Repurposed Drugs and Plant-Derived Natural Products as Potential Host-Directed Therapeutic Candidates for Tuberculosis.
Raqib R, Sarker P. · · 2024 · cited 4× · PMID 39766204 · DOI 10.3390/biom14121497
Verify or expand the search:
- PubMed search for NCT05073965
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Vitamin D
Trials testing the same drug.
- NCT07366086 — Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta · Phase 3 · recruiting
- NCT07458815 — Vitamin D for Acute Intracerebral Hemorrhage · NA · not yet recruiting
- NCT07491965 — Association Between Benign Paroxysmal Positional Vertigo and Vitamin D Deficiency . · not yet recruiting
- NCT07400757 — Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease · NA · not yet recruiting
- NCT07293910 — Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Py · Phase 2 · recruiting
Other recruiting trials for Tuberculosis, Pulmonary
Currently open trials in the same condition.
- NCT07077213 — 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients · recruiting
- NCT07271225 — Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting · NA · recruiting
- NCT06845618 — Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment · recruiting
- NCT06253715 — Shortened Regimen for Drug-susceptible TB in Children · Phase 3 · recruiting
- NCT06057519 — Pragmatic Optimized Rifampicin Trial · Phase 3 · recruiting
Other Universitas Padjadjaran trials
Trials by the same sponsor.
- NCT07506486 — Effect of Immersive Virtual Reality Cognitive Rehabilitation on Subacute Stroke Patients (A Pilot Study) · NA · not yet recruiting
- NCT07494357 — Effects of Dual Task-Oriented Circuit Training on Walking Recovery in Sub-acute Stroke · NA · not yet recruiting
- NCT07451899 — TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease · not yet recruiting
- NCT07467954 — Comparative Effectiveness of Long-Pulsed 1064-nm Nd:YAG and Fractional CO₂ Laser in Skin Rejuvenation · NA · recruiting
- NCT07344688 — The Effect of White Tea in Healthy Human Subjects · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05073965 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitas Padjadjaran
- Last refreshed: 12 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05073965.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing